SCHEMBL30108554

SCHEMBL30108554

CC(=O)c1ccc(OC(F)F)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.49
RAB9A P51151 2/20 0.49
LMNA P02545 1/20 0.49
MAPK1 P28482 1/20 0.49
CREBBP Q92793 1/20 0.41
PDE4D Q08499 5/20 0.41
PDE4A P27815 4/20 0.41
PDE4B Q07343 4/20 0.41
PDE4C Q08493 4/20 0.41
KCNQ3 O43525 1/20 0.41
KCNQ2 O43526 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 2/20 0.40
GAA P10253 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2279735 1.00 HTT (0.49) HTTRAB9ALMNAMAPK1CREBBP
SCHEMBL1091884 0.86 KCNQ3 (0.53) HTTRAB9ALMNAMAPK1CREBBP
SCHEMBL16956490 0.86 HTT (0.43) HTTRAB9ALMNAMAPK1PDE4D
SCHEMBL142851 0.86 PDE4D (0.54) HTTRAB9ALMNAMAPK1CREBBP
SCHEMBL30147631 0.84 HTT (0.64) HTTRAB9ALMNAMAPK1PDE4D
SCHEMBL20042919 0.84 HTT (0.64) HTTRAB9ALMNAMAPK1PDE4D
SCHEMBL31475537 0.83 HTT (0.50) HTTRAB9ALMNAMAPK1KCNQ3
SCHEMBL6581028 0.83 HTT (0.50) HTTRAB9ALMNAMAPK1KCNQ3
SCHEMBL23834769 0.83 HTT (0.45) HTTRAB9ALMNAMAPK1PDE4D
SCHEMBL3596045 0.83 PKM (0.42) HTTRAB9ACREBBPPDE4DPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4598923-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS The Regents of the University of California (US) 2025-08-13 EP disclosed
US-20240279227-A1 FUSED HETEROCYCLIC DERIVATIVES JANSSEN BIOTECH, INC. 2024-08-22 US disclosed
CN-117881661-A Condensed heterocyclic derivative 杨森科学爱尔兰无限公司 2024-04-12 CN disclosed
EP-4347036-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2024-04-10 EP disclosed
WO-2024059845-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-21 WO disclosed
WO-2022253255-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279227-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 HTT 1974/4885RAB9A 592/4885LMNA 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.